1. Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
- Author
-
Oudard, Stephane, Benhamouda, Nadine, Escudier, Bernard, Ravel, Patrice, Tran, Thi, Levionnois, Emeline, Negrier, Sylvie, Barthelemy, Philippe, Berdah, Jean François, Gross-Goupil, Marine, Sternberg, Cora N., Bono, Petri, Porta, Camillo, Giorgi, Ugo De, Parikh, Omi, Hawkins, Robert, Highley, Martin, Wilke, Jochen, Decker, Thomas, and Tanchot, Corinne
- Subjects
- *
RENAL cell carcinoma , *MYELOID cells , *NEOVASCULARIZATION inhibitors , *PATIENT preferences , *METASTASIS - Abstract
The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+CD14 and Tie2+CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+CD14 and Tie2+CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF